11 articles
H.B. Fuller's board rejected Ancora's $1.1–1.2 billion offer for its Building Adhesive Solutions unit, citing undervaluation and strong future growth prospects. The company remains confident in the se
H.B. Fuller's board rejected Ancora Holdings' $1.1-1.2 billion offer for its building adhesives solutions (BAS) unit, citing undervaluation. The company plans to integrate its AMS acquisition while ma
Ankola Holdings proposed a $1.1–1.2 billion cash deal to acquire H.B. Fuller’s construction adhesive business, aiding Fuller's strategic pivot to specialty adhesives. The unit generated $860 million i
Activist investor Ancora Holdings Group proposed acquiring H.B. Fuller's building adhesives segment for $1.1–1.2 billion in cash, escalating its campaign against the US adhesives producer.
H.B. Fuller proposed a £715 million acquisition of wound-care supplier AMS, facing criticism from activist investor Ancora Holdings who urged deleveraging. The deal aims to expand market reach and ach
H.B. Fuller set 2030 sustainability targets including a 25% reduction in Scope 1 GHG emissions and a 75% increase in recycling rates against a 2025 baseline. The adhesive maker also aims to cut water
Activist investor Ancora urges H.B. Fuller to halt its acquisition of Advanced Medical Solutions Group due to leverage concerns. H.B. Fuller defends its M&A strategy and commitment to deleveraging whi
US adhesives maker H.B. Fuller launched an unsolicited takeover bid for UK medical supplier Advanced Medical Solutions, lifting shares 13.5% following failed private equity negotiations.
H.B. Fuller plans to construct an innovation center in Charlotte, NC, targeting aviation, space, and defense markets by early 2027. The facility will consolidate manufacturing and testing operations t
H.B. Fuller posted adjusted earnings of 57 cents per share, beating consensus estimates of 55 cents, citing raw material cost savings as a key driver.
H.B. Fuller exceeded financial estimates despite a decline in sales volume. The company forecasts mild revenue and adjusted EBITDA increases for fiscal 2026.
ChemBrief